Small nucleolar RNA is potential as a novel player in leukemogenesis and clinical application

Li-Min Lin, Qi Pan, Yu-Meng Sun, Wen-Tao Wang

MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory for Biocontrol, School of Life Sciences, Sun Yat-Sen University, Guangzhou, Guangdong 510275, China

Abstract
Lack of clarity of the mechanisms that underlie leukemogenesis obstructs the diagnosis, prognosis, and treatment of leukemia. Research has found that small nuclear RNA (snoRNA) plays an essential role in leukemia. These small non-coding RNAs are involved in ribosome biogenesis, including the 2'-O-methylation and pseudouridylation of precursor ribosomal RNA (pre-rRNA), and pre-rRNA splicing. Recently, many snoRNAs were found to be orphans that have no predictable RNA modification targets, but these RNAs have always been found to be located in different subcellular organelles, and they play diverse roles. Using high-throughput technology, snoRNA expression profiles have been revealed in leukemia, and some of the deregulated snoRNAs may regulate the cell cycle, differentiation, proliferation, and apoptosis in leukemic cells and confer drug resistance during leukemia treatment. In this review, we discuss the expression profiles and functions of snoRNAs, particularly orphan snoRNAs, in leukemia. It is possible that the dysregulated snoRNAs are promising diagnosis and prognosis markers for leukemia, which may serve as potential therapeutic targets in leukemia treatment.

Keywords: 2'-O-methylation, Biomarkers, Drug resistance, Leukemia, snoRNA, Targeted therapy

1. INTRODUCTION
Leukemia is a type of blood cancer caused by the malignant proliferation of hematopoietic cells that can infiltrate the bone marrow, blood, lymph nodes, spleen, and other tissues. Patients with leukemia may suffer severe infections, anemia, and bleeding.1-4 According to the 2016 World Health Organization classification guidelines, clinical practice integrates cell morphology, immunophenotype, genetics, and cytogenetics to diagnose and prognose leukemia.5 Although several predisposing factors including genetic susceptibility and environmental factors have been identified, the mechanism of leukemogenesis remains unclear, which makes it difficult to diagnose and prognose leukemia in many cases.1-4 Further discoveries of the molecular characteristics of leukemia may provide new perspectives on diagnostic and prognostic markers. Recently, due to advances in synthesizing technology, snoRNA expression profiles have been revealed in leukemia, and some of the deregulated snoRNAs may regulate the cell cycle, differentiation, proliferation, and apoptosis in leukemic cells and confer drug resistance during leukemia treatment. In this review, we discuss the expression profiles and functions of snoRNAs, particularly orphan snoRNAs, in leukemia. It is possible that the dysregulated snoRNAs are promising diagnosis and prognosis markers for leukemia, which may serve as potential therapeutic targets in leukemia treatment.

snoRNAs are a type of small non-coding RNAs that are mainly located in the nucleolus of eukaryotic cells.10,11 It has been demonstrated that snoRNAs can be directly transcribed from genes or they may be encoded in the introns of other coding genes.12 These molecules are usually complex with diverse sets of proteins to form small nucleolar ribonucleoprotein particles (snoRNPs), which perform multiple functions.13 The canonical functions of snoRNAs include ribosomal biogenesis, including the modification and splicing of precursor ribosomal RNA (pre-rRNA),14,15 and mediating small nuclear RNA (snRNA) modification.16 Some snoRNAs are found to regulate the translation and processing of message RNA (mRNA),17 or they function in a manner similar to microRNAs (miRNAs).18,19 Dysregulated snoRNAs can affect tumorigenesis and progression by regulating the cell cycle,20 proliferation,21 differentiation,22 oxidative stress,23 and apoptosis.24,25 In recent years, several researchers have also reported the involvement of snoRNAs in the differentiation, proliferation, and apoptosis of leukemic cells and their potential as prognostic biomarkers and therapeutic targets.26-30 In this review, we provide an overview of snoRNA function, their expression patterns, and their clinical significance in leukemia. Uncovering the functions of diverse snoRNAs may improve understanding of the underlying biological events in leukemogenesis, ultimately leading to the discovery of novel therapeutic targets and biomarkers and new perspectives for the future design of nucleic acid therapeutics.
2. BIOGENESIS AND FUNCTION OF snoRNAs

2.1. Biogenesis and location of snoRNAs

snoRNAs can be directly transcribed by snoRNA genes with independent promoters, or they may be encoded by intronic snoRNA genes that lack independent promoters (Fig. 1A). Both types of snoRNA genes can be distributed individually or in a cluster, and the latter depends on enzymatic processing of a polycistronic precursor RNA to produce a single snoRNA. Several snoRNAs are transcribed by RNA polymerase II, whereas the transcription of other snoRNAs is driven by the upstream pol III-specific box A and box B. Based on conserved sequence elements, snoRNAs are classified as C/D box or H/ACA box snoRNAs.

snoRNAs have long been the best-studied class of ncRNAs and have an unglamorous but important role in the protein synthesis machinery. The canonical functions of snoRNA are realized by guiding 2'-O-methylation and pseudouridylation of rRNA in a base-pair dependent manner by C/D box and H/ACA box snoRNAs, respectively (Fig. 1B). However, a subset of snoRNAs called orphan snoRNAs have no predictable RNA modification targets, and therefore largely unknown function. In addition, sporadic reports have indicated that snoRNAs could exert non-canonical functions by mediating alternative splicing, RNA–RNA interactions, processing into small ncRNAs, and forming non-canonical snoRNPs.

In recent years, except for the canonical snoRNAs that are located in the nucleolus and regulate 2'-O-methylation and pseudouridylation during ribosome biogenesis, snoRNAs are found located in many different subcellular organelles and play diverse roles. Several snoRNAs were found in mitochondria to interact with the RNase mitochondrial RNA processing enzyme.
(MRP), which plays a role in cartilage-hair hypoplasia. These snoRNAs are non-canonical snoRNAs that do not belong to either the C/D box or H/ACA box classes. Small Cajal body (CB)-specific RNAs (scaRNAs) are a subset of canonical snoRNAs that are found in CBs. It has been found that the location of scaRNAs is dependent on CAB boxes (UGAG) or long UG (GU) dinucleotide repeat elements. scaRNAs have been demonstrated to function as guide RNAs during the site-specific synthesis of 2'-O-ribose-methylated nucleotides and pseudouridines for RNA polymerase II-transcribed U1, U2, U4, and U5 spliceosomal small nuclear RNAs (snRNAs) (Fig. 1C). Notably, recent evidence of high enrichment of snoRNAs in chromatin-bound fractions open the possibility that they might play a role in chromatin biology. The new tricks for these "old dogs" and the elusive roles of orphan snoRNAs restimulate interest in investigating the diverse functions of snoRNAs, particularly orphan snoRNAs that have no canonical targets.

2.2. snoRNAs in ribosome biogenesis

The canonical roles of snoRNAs are on ribosome biogenesis. A ribosome is a molecular machine for protein synthesis that is responsible for translating the information contained in mRNA into protein. In eukaryotes, the 60S subunit of the ribosome is composed of 28S, 5.8S, and 5S rRNAs and 46 proteins, while the 40S small subunit contains 18S rRNA and 33 proteins. Ribosome biogenesis in eukaryotes is mainly performed in the nucleolus in a complex process involving the transcription of both ribosomal DNA (rDNA) and ribosomal protein (RP) DNA, the translation of RPs, the modification and processing of pre-rRNA, and the assembly of ribosomal subunits. Numerous lines of evidence have shown that snoRNAs play important roles in the post-transcriptional modification, processing of pre-rRNAs, and ribosome biogenesis. Most snoRNAs are responsible for the 2'-O-methylation of specific nucleotides in pre-rRNAs and the conversion of specific uridines into pseudouridine (Fig. 2). Some snoRNAs are involved in the processing of pre-rRNAs. For example, U3, U14, snR10, snR30, and MRP/7-2 are necessary for the maturation of yeast 18S rRNA, and U8 plays an important role in the processing of 28S rRNA. Interestingly, there appears to be no consistent positional relationship between snoRNA binding sites and pre-RNA splicing sites. Thus far, the functional mechanism of snoRNAs involved in pre-RNA processing remains unclear. Whether snoRNAs function as a significant component of the processing complex or if they affect processing by changing the conformation of pre rRNA remains to be verified.

2.2.1. snoRNAs in 2'-O-methylation

The box C/D snoRNA family possesses the conserved nucleotide boxes C and D, which are both conducive to the stability of box C/D snoRNAs. In the structure of the box C/D snoRNAs, the C and D boxes are respectively located near the 5' and 3' ends of the snoRNA. The two elements are gathered together by their adjacent complementary short sequences, while the middle region of the snoRNA remains loose with the box C and box D elements, which are 1 to 2 bases away from where box C and box D are located. Upstream of the D or D' box exists a long sequence, which can be completely complementary to the internal rRNA sequence. The two conserved box elements have different functions. The C/C' boxes are necessary for binding fibrillarin, while the D or D' boxes mediate site selection for rRNA 2'-O-methylation by base pairing. During the 2'-O-methylation mediated by box C/D snoRNAs, the antisense snoRNAs in snoRNPs binds a complementary sequence in pre-rRNA to form a double helix, and the nucleotide opposite the fifth nucleotide, which is upstream of the snoRNA D or D' box, is recognized and modified by fibrillarin (Fig. 2A). rRNA 2'-O-methylation optimizes the structure of rRNA, leading to the production of

![Figure 2.](image-url)
ribsomes with high activity and high-fidelity (Fig. 1B). In addition, rRNA 2'-O-methylation may promote the activity of the translation mediated by the internal ribosome entry site. These findings suggest that snoRNAs may be involved in some biological events by altering the translation mechanism in cells.

2.2.2. snoRNAs in pseudouridylation. The H/ACA snoRNA family possesses an evolutionarily conserved “hairpin-hinge-hairpin-tail” structure, and the box H and box ACA are respectively located in the single-stranded region and 3' end of H/ACA snoRNA. H/ACA snoRNAs mediate site selection of rRNA pseudouridylation (Fig. 2B). The hairpin structure that is adjacent to the H or ACA box forms a pseudouridylation pocket, and this pocket can be complementary to the sequences flanking the rRNA modification site (Fig. 1B). The unpaired uridine (14–16 nt away from the H or ACA box) in the pocket is recognized and converted to pseudouridine by the H/ACA snoRNA. Compared to uridine, the pseudouridine in rRNA has three potential functions: (1) the more flexible C–C glycosyl bond may alter the rRNA folding or conformation; (2) the N-1 proton of pseudouridine can serve as an extra H-bond donor in the intramolecular interaction of rRNA or in rRNA-protein interactions, which may influence rRNA or rRNA-protein conformations; and (3) the N-1 position has a high potential for acyl transfer, which can catalyze the transfer of the growing peptide from the ribosomal P site to the A site and therefore alter the translational activity. The loss of rRNA pseudouridine may lead to defective small subunits or conformational changes in the peptidyl transferase center (PTC) of large ribosome subunits, thereby impairing the translation activity of ribosomes. Additionally, the pseudouridine in rRNA was found to have the potential to stabilize its adjacent nucleotides and was therefore suggested to influence the fidelity of the ribosome by stabilizing the key nucleotide in PTC. However, it appears that not all pseudouridines in rRNA are indispensable. Highly conserved pseudouridines may function significantly, while others may have subtle or even no effect. In addition, the loss of more than one snoRNA was found to improve the subtle effects caused by a single snoRNA, suggesting that synergy may exist among cellular snoRNAs. The functional mechanism of snoRNA-mediated pseudouridylolation is complicated, and analysis of H/ACA snoRNA expression profiles based on high throughput technology may provide new perspectives.

2.2.3. snoRNAs with other functions. Recent studies have shown that snoRNAs possess additional functions. MRPA RNA is a non-canonical snoRNA that is an important component of ribonuclease mitochondrial RNA processing (RNase MRP) that plays an important role in pre-rRNA processing and cell-cycle regulation. It has been reported that MRPA RNA can also serve as a component of RNase P to regulate the processing of pre-tRNA. RNase MRPA and RNase P are closely related in both evolution and structure; however, their substrate specificity and substrate recognition mechanism are quite different, leading to distinct functions. In addition, scaRNAs contain a C/D box and/or a H/ACA box, and they serve as regulatory molecules that mediate post-transcriptional modification of spliceosomal small nuclear RNAs, including 2'-O-methylation and pseudouridylolation (Fig. 1C). These modifications are essential to form an active spliceosome, and influence the subsequent splicing of pre-mRNA. Recently, approximately half of the human snoRNAs were termed “orphans” because they have no sequence complementarity and lack known targets, which suggests additional functions for this class of RNAs. For instance, the “orphan” neuron-specific SNORD115 plays an important role in alternative splicing. SNORD115 binds to the dsRNA structure of serotonin receptor 2C pre-mRNA and provides the inclusion of exon Vb into the mRNA, generating a normal receptor with high sensitivity to serotonin (Fig. 1D). Lykke-Andersen et al reported that snoRD86 acts in cis as a sensor and controls the alternative splicing of its host transcript Nuclear Protein 56 (NOP56) via a structural “switching” mechanism. SNORD88C has also been demonstrated to have base complementarity to an intronic region of fibroblast growth factor receptor 3 (FGFR3), and it increases exon inclusion in the FGFR3 gene transcript. Interestingly, snoRNAs have also been reported to bind to poly ADP-ribose polymerase 1 (PARP1), a ubiquitously expressed nuclear enzyme that plays key roles in DNA repair and gene regulation. However, snoRNAs stimulate PARP1 catalytic activity in the nucleolus independent of DNA damage. Activated PARP1 ADP-ribosylates DDX21, an RNA helicase, and then localizes to nucleoli and promotes rDNA transcription (Fig. 1E). The selectivity activation modes of special snoRNAs may suggest that snoRNAs can change traditional regulatory outcomes. Of note, several snoRNAs are enriched in chromatin and are suggested to play a role in chromatin biology. Drosophila decondensation factor D31 (D31) mediates the link between snoRNAs and chromatin and regulates an RNA-chromatin network, resulting in the establishment of open chromatin domains and RNA transcription (Fig. 1F).

Recent studies have revealed that a large proportion of snoRNAs are further processed into smaller molecules. The function of these small molecules is mostly unknown except for a subset of them that has been shown to perform a regulatory function like microRNAs (Fig. 1G). Interestingly, sunny Sharma et al demonstrate that a novel role for box C/D snoRNAs can guide 18S rRNA acetylation and aid early pre-rRNA processing in yeast. Further research of the relationship between snoRNAs and their processed smaller molecules and diverse rRNA modifications may contribute to the understanding of the unknown functions of snoRNAs.

3. EXPRESSION AND FUNCTION OF SNORNAs IN LEUKEMIA

According to disease progression and cell lineage, leukemia can be divided into several subtypes: chronic lymphocytic leukemia (CLL), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), and acute myeloid leukemia (AML). In recent years, snoRNAs have been found to have different expression profiles in the different leukemia subtypes, and they regulate leukemogenesis and progression through diverse regulation modes.

3.1. snoRNAs in AML

AML is a malignant disorder of hematopoietic stem cells characterized by clonal expansion of abnormally differentiated myeloid lineage blasts. A few snoRNAs are regulated in a lineage- and development-specific manner and play a role in the biogenesis and progression of AML (Fig. 3). In t(8;21) AML, the expression of a subset of C/D box snoRNAs was stimulated by the fusion gene and subsequently promoted the self-renewal of AML cells (Fig. 3A). The fusion protein AML1-ETO induces the expression of the amino-terminal enhancer of split (AES), which subsequently up-regulates the expression of C/D box snoRNA and promotes the formation of snoRNP by interacting...
with the RNA helicase DDX21.\textsuperscript{26} Similarly, other AML-related oncogenes, including MYC and MLL-AF9, can also up-regulate snoRNA expression, but this process does not depend on AES.\textsuperscript{26} These data indicate that the regulation of AML-related oncogenes by snoRNA is complicated. Although the functional mechanism by which C/D box snoRNPs promote the proliferation of AML cells is unclear, research has shown that a decrease in the level of 2'-O-methylation is accompanied by down-regulation of C/D box snoRNAs.\textsuperscript{26} It has been reported that C/D box snoRNAs mediate the 2'-O-methylation of pre-rRNA, and this modification may influence the translational activity and fidelity of ribosomes.\textsuperscript{39,44,45} Additionally, acceleration of protein synthesis was suggested to be necessary for the proliferation of cancer cells.\textsuperscript{38} Therefore, it is reasonable that C/D box snoRNAs...
may regulate AML by changing the translational activity of ribosomes through mediating the 2'-O-methylation of pre-rRNA. Interestingly, a subset of snoRNAs related to ribosome biogenesis was found to be dysregulated in AML. For instance, SNORD42A was reported to act as a C/D box snoRNA to mediate the 2'-O-methylation of 18S-U116 in the 40S subunit, which may change the translation preference of the ribosome by affecting its 3D structure, thereby promoting cell proliferation (Fig. 3B).

In addition to the canonical functions of pre-rRNA modification, recent studies have shown that snoRNAs possess additional functions in AML progression. The DLK1-DIO3 locus, which is located in imprinted regions, was found to be related to leukemogenesis and progression. This locus encodes a number of ncRNAs, including 41 snoRNAs, 11 lncRNAs, and 53 miRNAs, and the snoRNAs have been reported to be expressed in a lineage- and development-specific manner during hematopoiesis. For example, the expression of these snoRNAs was highest in CD34+ cells, and it rapidly decreased throughout differentiation, remaining at a low level in mature neutrophils.

In the DLK1-DIO3 locus, a variety of snoRNAs were downregulated in AML and related to both ribosome biogenesis and the mRNA splicing complex, while SNORD112-114 was upregulated in promyelocytic leukemia. Among these snoRNAs, SNORD114-1 could regulate the cell cycle transition (from Go/G1 to S phase) mediated by the Rb/p16 pathway to promote the cell cycle transition (from G0 to S phase) mediated by the Rb/p16 pathway to promote the growth of AML cells (Fig. 3C). The snoRNAs encoded by the DLK1-DIO3 locus might serve as regulatory molecules in several biological events involved in AML, including the development of the hematopoietic system, ribosome translation, mRNA processing, and cell cycle transition. Another study has shown that epigenetic silencing of the DLK1-DIO3 locus inhibits the pluripotency of induced pluripotent stem cells (iPSCs). The roles of the intronic snoRNAs encoded in the DLK1-DIO3 locus in the pluripotency of stem cells remain to be studied.

### 3.2. snoRNAs in ALL

ALL involves the malignant proliferation of lymphoid cells blocked at an early stage of differentiation. In ERG-related leukemia, a subtype of B cell precursor acute lymphoblastic leukemia (BCP-ALL), several snoRNAs in the Prader-Willi locus were found to be specifically upregulated, including SNORD109A, SNORD64, SNORD107, and 12 snoRNAs in the SNORD116 cluster (SNORD116-11, -14, -15, -16, -17, -18, -20, -21, -22, -23, -24, and -27) (Table 1). Similarly, SNORD116-18 was also upregulated in CLL patients and found to be associated with shorter progression-free survival (PFS).

Thus far, most of the snoRNAs in the Prader-Willi locus except SNORD115 are orphan snoRNAs with no known target or function. SNORD115 was reported to regulate the alternative

#### Table 1

| snoRNAs | Subtype | Expression | Function | Reference |
|---------|---------|------------|----------|-----------|
| SNORD34, SNORD35A, SNORD43 | AML1-ETO AML | Up | rRNA methylation, protein synthesis | 28 |
| SNORD14D | AML1-ETO AML | Up | Clonogenic growth | 28 |
| SNORD14D, SNORD35A | Biphenotypic B-myelomonocytic leukemia | Up | Colony formation | 28 |
| SNORD114-1, SNORD112, SNORD113-7, SNORD113-8, SNORD113-9 | acute promyelocytic leukemia (APL) | Up | | 20 |
| SNORD109A, SNORD64, SNORD107 and 12 snoRNAs in the SNORD116 cluster (SNORD116-11, -14, -15, -16, -17, -18, -20, -21, -22, -23, -24, -27) | B cell precursor acute lymphoblastic leukemia (BCP ALL) | Up | Unknown | 66,67 |
| SNORD116-18, SNORA7A | CLL | Up | Associated with shorter PFS | 67 |
| SNORD56, SNORD1A, SNORA70F | CLL | Down | Associated with shorter PFS | 67 |
| SNORA31, -6, -62, and 71C | CLL | Down | Guilt target miRNAs pseudouridylation | 67 |
| SNORA12, -22, -27, -56, -64, -69, -70, -74A, -80, -84, SNORD1A, -18, -8, 18A, -30, -32A, -34, -105B, -110; SCARN8 | IGH-M CLL | Up | Associated with shorter TFS, cell proliferation | 24 |
| U50, U50’ | B-cell lymphoma | Normal | Cell growth | 74,75,76 |
| ACA11 | t(4;14)-positive multiple myeloma | Up | Oxidative stress, doxorubicin resistance, cell growth | 22,23,26 |
splicing of serotonin receptor 2C pre-mRNA, and its loss may contribute to Prader-Willi syndrome. The hypothesis that some orphan snoRNAs in the Prader-Willi locus function in the same manner as SNORD115 remains to be verified.

Growth Arrest Specific 5 (GAS5) is a multi-small-nucleolar-RNA host gene that can be transcribed into long non-coding RNA (lncRNA GAS5) and encode snoRNA. GAS5 plays an essential role in growth arrest and apoptosis. Overexpression of GAS5 leads to an increase in cell apoptosis and a cell cycle arrest in both leukemic and normal T lineage cells. In Friend leukemia and breast cancer, GAS5 was reported to be down-regulated, which leads to apoptosis inhibition and aberrant proliferation. Similarly, RNU44, a snoRNA encoded by GAS5, was normally upregulated to arrest cell growth under stress, and its lower expression is associated with poor prognosis in breast cancer. The relationship between the functional mechanism of GAS5 and that of RNU44 remains unknown. However, sequence analysis reveals that only intronic snoRNAs are highly conserved in GAS5, suggesting that snoRNAs significantly contribute to GAS5 function. As the aberrant proliferation of T lineage cells can lead to ALL, aberrant growth arrest in T lineage cells by GAS5, or perhaps by the intronic snoRNA, may significantly affect ALL development. Moreover, GAS5 is involved in chromosomal translocation in lymphoma, for example, the GAS5 gene fused to BCL6 was found in B-cell lymphoma. Whether snoRNAs co-transcribe with the GAS5 host gene and have functional effects in lymphoid leukemia requires further research.

3.3. snoRNAs in CLL

CLL is a lymphoproliferative disorder that is characterized by the expansion of neoplastic B lymphocytes in the peripheral blood, secondary lymphoid tissues, and bone marrow. An analysis of the sno/scaRNA expression profile in CLL demonstrated that SNORA31, SNORA6, SNORA62, and SNORA71C are all down-regulated (Table 1). These snoRNAs are canonical H/ACA snoRNAs, which mediate the site-specific pseudouridinization of rRNA. It is not clear whether these snoRNAs have pathological effects; however, it is worth noting that their host genes play roles in tumor-related signal transduction. For example, TPT1, the host gene of SNORA31, can directly or indirectly regulate the expression of the p53 gene and consequently influence cell growth, proliferation, tumor reversal, and reprogramming of both embryonic stem cells and tumor cells. It has been reported that upregulated expression of SNORD116-18, SNORA70F, SNORA74A, SNORD56, and SNORD1A is relevant to shorter PFS in CLL patients. Although the functions of these snoRNAs remain unclear, they were suggested to be involved in the regulation of alternative splicing mRNAs. The snoRNA expression profiles of additional CLL cases were analyzed in another study reporting that the overexpression of 20 snoRNAs was associated with the short treatment-free survival (TFS) of IGHV-mutated (IGHV-M) patients, and that most of the 20 snoRNAs could be functionally relevant in CLL cell proliferation. Furthermore, after CLL cells were induced to proliferate, 7 snoRNAs continued to be up-regulated with proliferation, while 2 snoRNAs (SNORA80 and SNORD1A) were down-regulated. It is evident that snoRNAs are subject to complex regulation during the proliferation of CLL cells. Some snoRNAs may be deregulated during proliferation, whereas others may continue to be up-regulated, and the latter likely have important regulatory functions.

3.4. snoRNAs in other hematologic neoplasms

snoRNAs also have functional effects in other hematologic neoplasms. The intrinsic U50 snoRNA gene is located at chromosomal breakpoint t(3;6)(q27;q15) in human B-cell lymphoma, and the encoded U50/U50 snoRNA acts as C/D box snoRNA to mediate site-specific 2'-O-methylation in 28S rRNA. 2'-O-methylation has been considered a promising functional mechanism of U50/U50 snoRNA in lymphogenesis. Although the role of U50 snoRNA is unclear, it has been suggested that U50 snoRNA is a candidate for the 6q tumor suppressor gene in other human cancers. For example, snoRNA U50 usually undergoes a copy loss, a 2-bp deletion, and downregulation in both breast and prostate cancer, and reexpression of snoRNA U50 was found to inhibit the colony-forming ability of breast cancer cells, suggesting that snoRNA U50 has the potential to suppress tumorigenesis. An orphan box H/ACA snoRNA, ACA11, was found to be highly expressed in t(4;14)-positive multiple myeloma (MM), and this snoRNA suppressed oxidative stress, provided resistance to chemotherapty, and increased the proliferation of MM cells. Unlike canonical H/ACA snoRNA, ACA11 appears to be involved in an RNA processing complex, suggesting that it may regulate cellular RNA processing. Further research showed that ACA11 regulates the ROS level by inhibiting the expression of nuclear factor (erythroid-derived 2)-related factor 2 (NRF2), and it stimulated ribosome biogenesis and protein synthesis in a ROS-dependent manner to promote proliferation. Although these discoveries have revealed a partial mechanism of ACA11, the targets of this orphan snoRNA remains unknown. A study of the sno/scaRNA profile in MM has revealed the specific dysregulated snoRNAs and their potential function. Unveiling the direct targets of these snoRNAs may provide new perspectives on their functional mechanism.

4. EXPRESSION PATTERN OF LEUKEMIA-RELATED SNORNAS AND THEIR CLINICAL SIGNIFICANCE

4.1. Leukemia-related snoRNAs in drug resistance

With the development of chemotherapy and molecular targeting drugs, the treatment of leukemia has improved, leading to an increased survival rate. However, drug resistance remains a critical problem in leukemia treatment. The discoveries of snoRNAs have provided new perspectives for dealing with drug resistance in leukemia. GAS5, a multi-small-nucleolar-RNA host gene, regulates apoptosis and the growth arrest of T cells, and its downregulation promoted Friend leukemia. Interestingly, SNORD44, an intronic snoRNA in GAS5, was reported to regulate apoptosis and growth arrest in breast cancer. Because apoptosis failure is tightly associated with drug resistance in cancer, GAS5 and SNORD44 may play essential roles in drug resistance. This hypothesis was partially confirmed by the report that down-regulation of GAS5 rescued leukemic T cells from rapamycin, an mTOR antagonist. As SNORD44 is highly conserved in GAS5, it has been suggested to be a significant functional component of the GAS5 gene, which is consistent with a study reporting that it shares a similar function with GAS5. Together, these findings suggest that SNORD44 may be involved in rapamycin drug resistance in leukemia. Although relevant research in leukemia is limited, the evidence that snoRNAs function in drug resistance has been reported in other human cancers. For example, the expression of the H/ACA box snoRNA ACA11 in MLL15 cells reduced the level of ROS and increased resistance to doxorubicin,
suggesting that ACA11 rescues cells from cytotoxic chemotherapy (Table 1). Indeed, snoRNAs have become promising targets for treatment in drug-resistant leukemia.

4.2. Leukemia-related snoRNAs in targeted therapy

snoRNAs may affect the biogenesis and progression of leukemia by regulating cell cycle, proliferation, differentiation, and apoptosis. 26,27,28-30 suggesting that they are potential targets for leukemia treatment (Table 1). Some snoRNAs have been demonstrated to be upregulated in AML and promote this disease by altering ribosome activity. For example, SNORD42A was reported to mediate the 2'-O-methylation of 18S-U116 rRNA in the 4OS subunit, which might alter the translation preference of the ribosome, consequently promoting proliferation.29 A portion of snoRNAs regulate the cell cycle of cancer cells. It was reported that SNORD114–1 regulates the cell cycle transition mediated by the Rbp16 pathway in AML.30 Some studies on the snoRNA profile have revealed dysregulated snoRNAs in different subtypes of leukemia, including SNORD109A, SNORD64, SNORD107, SNORD116–18, SNORA31, SNORA6, SNORA62, SNORA71C, SNORA70F, SNORA74A, SNORD56, and SNORD1A.31,32 Among the dysregulated snoRNAs, SNORD116–18, SNORA70F, SNORA74A, SNORD56, and SNORD1A have been associated with shorter PFS for CLL patients.33 These snoRNAs are promising targets for leukemia therapy. On one hand, treatments should be administered to control the level of dysregulated snoRNAs in leukemia. We can improve the level of snoRNAs that suppress leukemia by transporting exogenous snoRNAs into leukemic cells, whereas the expression of snoRNAs that promote leukemia should be inhibited. On the other hand, competing for the downstream targets of snoRNAs may be a good strategy in targeted therapy whereby snoRNA function will be blocked.

4.3. Leukemia-related snoRNAs as diagnostic/prognostic markers

The snoRNA profile of leukemia has revealed that some snoRNAs are specifically upregulated or downregulated in different subtypes, suggesting that these snoRNAs are promising diagnosis and prognosis biomarkers. The snoRNA expression profiles of CLL were suggested to be heterogeneous in different subgroups,34-36 and expression of SNORA74A and SNORD116–18 could indicate two CLL groups with different PFS (Table 1).37 Similarly, there were significant differences between the snoRNA expression patterns in these leukemia subtypes, including AML, pre-B-ALL, and T-ALL.38 These findings indicate that the characteristics of snoRNA expression could be potential biomarkers for diagnosis and prognosis in leukemia, which may contribute to more effective treatment.

5. STRATEGIES USED TO STUDY THE ROLES AND MECHANISMS OF SNORNAS IN LEUKEMIA

snoRNAs are a class of metabolically stable RNAs, 60–300 nucleotide in length, that are excised from the intron regions of pre-mRNAs and located in the nucleolus.10,11 During the last decade, with the rapid development of biotechnology, snoRNAs have been found to have many novel, unexpected cellular functions and have been associated with leukemogenesis.26-30 Although several studies have reported the expression profiles and roles of snoRNAs in leukemia, the strategies used to uncover the comprehensive functions of snoRNAs on leukemogenesis are still defective. Here, we try to discuss and summarize the potential technologies used to study the roles and mechanisms of snoRNAs in leukemia. Firstly, genome-wide analysis with different omics techniques including GeneChip microarray on snoRNAs, high-throughput quantitative PCR of snoRNAs, and next-generation sequencing approaches, were applied to identify and quantify the global dysregulated snoRNAs in different subtypes of leukemia.26,27 Interestingly, Warner et al modified the cDNA library generation, which added an oligonucleotide adaptor to the 39-end of RNA before reverse transcription.27 Selecting the RNA species between 17 and 200 nucleotides, which includes snoRNAs and other sncRNAs and excludes most messenger RNA (mRNA) molecules, they obtained both annotated and novel snoRNAs using 2 complementary bioinformatics approaches.27 Following the genome-wide analysis, a real-time PCR assay with specific primers or northern blot with probes was always used to verify the dysregulated snoRNAs. Secondly, the majority of snoRNAs are excised from the pre-mRNA cytidine1703, a series of specific primers were designed to be used in the PCR procedure under high dNTP (1mM) and low dNTP (10μM) concentration, and the PCR products were loaded and separated on 2% agarose gels.28 SRNA, shRNA, and CRISPR/CAS9 were generally used to knock down or out the snoRNA and then the diverse functions in leukemia were detected, such as protein translation, cell differentiation, and cell growth.29 Of note, many of new-found snoRNAs called orphan snoRNAs have no predictable RNA modification targets, and therefore largely unknown function. However, orphan snoRNAs are unlikely to act alone, and always bind novel partners through their non-canonical structure,30 mass spectrometry was generally applied to identify unique protein shared with pull-down of snoRNA and followed by RNA immunoprecipitation.31-33 Since snoRNA has been found to become one of the important factor in leukemogenesis, more optimal strategies were needed to reveal the comprehensive functions and pathogenesis mechanisms of snoRNAs in the initiation and progression of leukemia in the future.

6. CONCLUSION

snoRNAs are involved in diverse cellular processes, including modification and splicing of pre-rRNA,14,15 snoRNA modification,16 and the translation and processing of mRNA.17 The 2’-O-methylation and pseudouridylation mediated by snoRNAs likely alter the activity of ribosomes, therefore promoting the biogenesis and progression of leukemia. In addition, because miRNAs have been reported to have a significant function in human cancer,34 it is likely that snoRNAs, which can be processed into miRNAs, may also play an essential role in leukemia. Undoubtedly, unveiling the novel functions of snoRNAs contributes to a more comprehensive understanding of leukemia.

Of note, in recent years, several snoRNAs were found to be located in many different subcellular organelles, and many of them are orphan molecules that may function by forming non-canonical snoRNPs. The elusive roles of orphan snoRNAs restimulate interest in investigating the diverse functions and
regulatory mechanisms of snoRNAs, particularly their roles in leukemia. Furthermore, snoRNA expression profiles based on high-throughput technology have revealed some dysregulated snoRNAs in leukemia, which provide the novel perspective that snoRNAs are promising biomarkers for diagnosis and prognosis and that they can serve as targets for treatment, particularly in drug resistance. Further research on the direct targets of the dysregulated snoRNAs may decrypt their functional mechanism. As for targeted therapy based on snoRNAs, there may be two potential strategies. One strategy is controlling the level of the dysregulated snoRNAs in leukemia, and the other focuses on potential strategies. One strategy is controlling the level of the dysregulated snoRNAs may decrypt their functional mechanism.

ACKNOWLEDGMENTS

We thank Yue-Qin Chen from School of Life Sciences, Sun Yat-sen University for their critical reading of the manuscript.

REFERENCES

[1] Short NJ, Ryting ME, Cortes JE. Acute myeloid leukaemia. Lancet 2018;392 (10147):593–606.
[2] Malard F, Mofidy M. Acute lymphoblastic leukaemia. Lancet 2020;395 (10147):1166–1162.
[3] Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to pathology and prognosis. Br J Cancer 2011;104 (7):1168–1177.

[22] Mei YP, Liao JP, Shen J, et al. Small nuclear RNA 42 acts as an oncogene in lung tumorigenesis. Oncogene 2012;31 (22):2794–2804.
[23] Zhang Y, Xu G, Gu D, et al. H/ACA box small nuclear RNA 7A promotes the self-renewal of human umbilical cord mesenchymal stem cells. Stem Cells 2017;35 (1):222–235.
[24] Chu L, Su MY, Maggi LB, et al. Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress. J Clin Invest 2012;122 (8):2793–2806.
[25] Michel C, Holley CL, Scruggs BS, et al. Small nuclear RNAs U32a, U33, and U35a are critical mediators of metabolic stress. Cell Metab 2011;14 (1):33–44.
[26] Zhou F, Liu Y, Rohde C, et al. AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. Nat Cell Biol 2017;19 (7):844–855.
[27] Warner WA, Spencer DH, Trissel M, et al. Expression profiling of snoRNAs in normal hematopoiesis and AML. Blood Adv 2018;2 (2):151–163.
[28] Tettitenn KJ, Laiho A, Uusimäki A, Pursiohimo JP, Gynesei A, Lohi O. Expression of small nuclear RNAs in leukaemic cells. Cell Oncol (Dordr) 2013;36 (1):55–63.
[29] Paul C, Liu Y, Rohde C, et al. Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for acute myeloid leukemia cell proliferation. Blood 2020;135 (23):2059–2070.
[30] Dixon-McClver A, East P, Mein CA, et al. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 2008;3 (5):e2141.
[31] Falaleeva M, Welden JR, Duncan MJ, Stamm S. C/D-box snoRNAs form methylating and non-methylating ribonucleoprotein complexes: old dogs show new tricks. Bioessays 2017;39 (6):e1600264.
[32] Steinbusch MME, Caron MMJ, Surelt DAM, et al. The antiviral protein p24 regulates chondrocyte differentiation via CXCL10 protein secretion. J Biol Chem 2019;294 (13):5121–5136.
[33] Chen XS, Penny D, Collins LJ. Characterization of RNase MRP RNA and novel snoRNAs from Giardia intestinalis and Trichomonas vaginalis. BMC Genomics 2011;12:550.
[34] Li X, Zhou B, Chen L, Gou LT, Li H, Fu XD. Grid-seq reveals the global localization of box H/ACA scaRNAs. Nucleic Acid Res Mol Biol 2014;395 (1):113–126.
[35] Chen J, Kunz S, Cignetti C, et al. Small nuclear RNAs: an abundant group of noncoding RNAs with diverse cellular functions. Cell 2020;180 (5):1471–1486.
[36] Ben-Shem A, Garreau de Loubresse N, Melnikov S, Jensen L, Yusupova G, Yusupov M. The structure of the eukaryotic ribosome at 3.0Å resolution. Science 2011;334 (6062):1524.
[37] Pollet JE, Thomas G, Volarevic S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer 2018;18 (1):51–63.
[38] Kiss-Lázsló Z, Henry Y, Bachellerie JP, Caizergues-Ferrer M, Kiss T. Site-specific ribose methylation of preribosomal RNA: a novel function for small nuclear RNAs. Cell 1997;86 (8):1077–1088.
[39] Ganor P, Bortolin M, Kiss T. Site-specific pseudouridine formation in preribosomal RNA is guided by small nuclear RNAs. Cell 1997;89 (5):799–809.
[40] Kiss T, Small nuclear RNAs: an abundant group of noncoding RNAs with diverse cellular functions. Cell 2002;109 (2):145–148.
[41] Caffarelli E, Fatica A, Predis P, De Gregorio E, Fragapane P, Bozzoni I. Processing of the intron-encoded U16 and U18 snoRNAs: the conserved C and D boxes control both the processing reaction and the stability of the mature snoRNA. EMBO J 1996;15 (5):1121–1131.
[42] Bajer JS, Yang XD, Steite JA. An intact Box C sequence in the U3 snoRNA is required for binding of fibrillarin, the protein common to the major family of nuclear snRNPs. EMBO J 1991;10 (10):2645–2651.
[43] Baxter-Roshelle JL, Petrov AN, Dinman JD. Optimization of ribosome structure and function by RNA base modification. PLoS One 2007;2(3):e174.
[44] Basu A, Das P, Chaudhuri S, et al. Requirement of RNA methylation for 80S ribosome assembly on a cohort of cellular internal ribosome entry sites. FEBS J 2008;275 (12):3228–3240.
[45] Nie J, Tien AL, Fourrier MJ. Small nuclear RNAs directly site-specific synthesis of pseudouridine in ribosomal RNA. Cell 1997;89 (4):565–573.
[46] Merchant M, Grohar PJ, Qiu J, Santalucia JJr, Scaringe SA, Chow CS. Unique structural and stabilizing roles for the individual pseudouridine residues in the 20S region of Escherichia coli 23S rRNA. Nucleic Acids Res 2000;28 (10):2075–2083.
[47] Ofengand J. Ribosomal RNA pseudouridines and pseudouridine synthases. FEBS Lett 2002;514 (1):17–25.
[49] Lane BG, Ofengand J, Gray MW. Pseudouridine in the large-subunit (23 S-like) ribosomal RNA: the site of peptide transfer in the ribosome. FEBS Lett 1992;302(1):1–4.

[50] King TH, Liu B, McCully RR, Fournier MJ. Ribosome structure and activity are altered in cells lacking snoRNPs that form pseudouridines in the peptidyl transferase center. Mol Cell 2003;11(2):425–435.

[51] Darzaqz N, Jady BE, Verheugen C, Kiss AM, Bertrand E, Kiss T. Cajal body-specific small nuclear RNAs: a novel class of 2′-O-methylated and pseudouridylation guide RNAs. EMBO J 2002;21(11):2746–2756.

[52] Will CL, Lührmann R. Spliceosomal UsnRNPs: architecture and function. Nat Rev Mol Cell Biol 2001;13(3):290–310.

[53] Kishore S, Stamm M. The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science 2006;311(5758):230–232.

[54] Kishore S, Khanna A, Zhang Z, et al. The snoRNA MBII-52 (SNORD 115) is processed into smaller RNAs and regulates alternative splicing. Hum Mol Genet 2010;19(17):1153–1164.

[55] Lykke-Andersen S, Ardal BK, Hollenser AK, Damgaard CK, Jensen TH. Box C/D snoRNA autoregulation by a cis-acting snoRNA in the NOP56 Pre-mRNA. Mol Cell 2018;72(1):99–111.e5.

[56] Scott MS, Ono M, Yamada K, Endo A, Barton GJ, Lamond AI. Human box C/D snoRNA processing conservation across multiple cell types. Nucleic Acids Res 2012;40(8):3676–3688.

[57] Kim DS, Camacho CV, Nagari A, Malladi VS, Challa S, Kraus WL. Activation of PARP-1 by snoRNAs controls ribosome biogenesis and cell growth via the RNA helicase DXD21. Mol Cell 2019;75(6):1270–1283.e14.

[58] Schubert T, Pusch MC, Diermeier S, et al. Df31 protein and snoRNAs of the serotonin receptor 2C small nuclear RNAs: a novel class of 2′-O-linked RNAs. Nucleic Acids Res 2002;21(11):2746–2756.

[59] Zhang Z, Pi J, Zou D, et al. microRNA arm-imbalance in part from complementary targets mediated decay promotes gastric cancer progression. Nat Commun 2019;10(1):4397.

[60] Sharma S, Yang J, van Noes R, et al. Specialized box C/D snoRNPs act as antisense guides to target RNA base acetylation. PLoS Genet 2017;13(5):e1006804.

[61] Bispo JA, Pinheiro PS, Kobetz EK. Epidemiology and etiology of acute myeloid leukemia. J Hematol Oncol 2020;13(1):128.

[62] Wu J, Xiao Y, Sun J, et al. A single-cell survey of cellular hierarchy in acute myeloid leukemia. J Hematol Oncol 2020;13(1):128.

[63] Dohner H, Weisflog DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015;373(12):1136–1152.

[64] Stadtfeld M, Apostolou E, Ferrari F, et al. Ascorbic acid prevents loss of self-renewal in normal long-term HSCs and multiple myeloma regulates ribosome biogenesis. Mol Cell 2017;69(3):435–445.

[65] Ronchetti D, Todoerti K, Tuana G, et al. The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis. J Hematol Oncol 2015;8(1):19.

[66] Bispo JA, Pinheiro PS, Kobetz EK. Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harb Perspect Med 2020;10(6):a034819.

[67] Li T, Zhou X, Wang X, Zhu D, Zhang Y. Identification and characterization of human snoRNA core promoters. Genomics 2010;96(1):50–56.

[68] Vendramini E, Giordani M, Giarran E, et al. High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. Oncotarget 2017;8(26):42399–42413.

[69] Ronchetti D, Mosca L, Cutrona G, et al. Small nuclear RNAs as new biomarkers in chronic lymphocytic leukemia. BMC Med Genomics 2013;6(1):27.

[70] Dupuis Sandoval F, Poirier M, Scott MS. The emerging landscape of small nuclear RNAs in cell biology. Wiley Interdiscip Rev RNA 2015;6(4):381–397.

[71] Mourauda-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. Growth arrest in human T-cells is controlled by the non-coding RNA growth- arrest-specific transcript 5 (GASS). J Cell Sci 2008;121(Pt 7):939–946.

[72] Mourauda-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GASS, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 2009;28(2):195–208.

[73] Coccia EM, Cicala C, Charlesworth A, et al. Regulation and expression of a growth arrest-specific gene (gas5) during growth, differentiation, and development. Mol Cell Biol 1992;12(8):3514–3521.

[74] Nakamura Y, Takahashi N, Kakegawa E, et al. The GASS (growth arrest-specific transcript 5) gene fuses to BCL6 as a result of (t(1;5)(q25; q27) in a patient with B-cell lymphoma. Cancer Genet Cytogenet 2018;182(2):144–149.

[75] Amson R, Pece S, Marine J-C, Fiore PPD, Teleman A. TPT1/CTCF-regulated pathways in phenotypic reprogramming. Trends Cell Biol 2013;23(1):37–46.

[76] Berquet L, Valleron W, Gregorevic S, et al. Small nuclear RNA expression profiles refine the prognostic impact of IGHV mutational status on treatment-free survival in chronic lymphocytic leukaemia. Br J Haematol 2016;172(5):819–823.

[77] Tanaka R, Sato H, Moriyama M, et al. Intronic U50 small-nucleolar-RNA (snoRNA) host gene of no protein-coding potential is mapped at the chromosome breakpoint t(3;6)(q27;q15) of human B-cell lymphoma. Genes Cells 2000;5(4):277–287.

[78] Dong XY, Guo P, Boyd J, et al. Implication of snoRNA U50 in human breast cancer. J Genet Genomics 2009;36(8):447–454.

[79] Dong XY, Rodriguez C, Guo P, et al. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet 2006;17(7):1031–1042.

[80] Mahajan N, Wu HJ, Bennett RL, et al. Sabotaging of the oxidative stress response by an oncogenic noncoding RNA. FASEB J 2017;31(2):482–490.

[81] Oliveira V, Mahajan N, Bates ML, et al. The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis. FASEB J 2019;33(7):404–414.

[82] Ronchetti D, Todoerti K, Tuana G, et al. The expression pattern of small nuclear and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. Blood Cancer J 2012;2(11):e96.

[83] Mourauda-Maarabouni M, Hasam AN, Farzaneh F, Williams GT. Inhibition of human T-cell proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest- specific transcript 5 (GASS). Mol Pharmacol 2010;78(1):19–28.

[84] Yoshimura M, Nakao A, Kemochi N. snoOPY: a small nuclear RNA orthological gene database. BMC Res Notes 2015;6:426.

[85] Xie J, Zhang M, Zhou T, Hua X, Tang L, Wu W. SnoScaRNAbase: a curated database for small nuclear RNAs and Cajal body-specific RNAs. Nucleic Acids Res 2007;35(Database issue):D183–D187.

[86] Yang JH, Zhang XC, Huang ZP, et al. snoSeeker: an advanced computational package for screening of guide and orphan snoRNA genes in the human genome. Nucleic Acids Res 2006;34(18):5112–5123.

[87] Schwartz S, Bernstein DA, Mumbach MR, et al. Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA. Cell 2014;159(1):148–162.

[88] Dai Q, Moskitch-Moskovitz S, Han D, et al. Nm-seq maps 2′O- methylation sites in human mRNA with base precision. Nat Methods 2017;14(7):695–698.

[89] Li X, Fu XD. Chromatin-associated RNAs as facilitators of functional genomic interactions. Nat Rev Genet 2019;20(9):503–519.

[90] Wang WT, Chen TQ, Zeng ZG, et al. The IncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia. J Hematol Oncol 2020;13(1):78.

[91] Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005;122(1):6–7.